You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Evolution of Checkpoint Inhibitors in Esophageal Squamous Cell Carcinoma: A Case Review

  • Authors: Jaffer Ajani, MD; Michelle Turner, MS, CRNP
  • CME / ABIM MOC / CE Released: 9/28/2022
  • Valid for credit through: 9/28/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    Nurses - 0.25 ANCC Contact Hour(s) (0.25 contact hours are in the area of pharmacology)

    IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, surgeons, gastroenterologists, oncology nurses, and nurse practitioners

The goal of this activity is for learners to be better able to apply new data and expert guidance on use of checkpoint inhibitors (ICIs) in managing patients with untreated ESCC.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical trial data for checkpoint inhibitor-based therapies used in ESCC
  • Have greater competence related to
    • Treatment of ESCC with checkpoint inhibitor-based therapies
    • Management of adverse events associated with checkpoint inhibitor-based therapies for ESCC
  • Demonstrate greater confidence in their ability to
    • Collaborate with members of the interprofessional team in coordinating care for patients with advanced or metastatic ESCC


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Jaffer Ajani, MD

    Professor of Medicine
    Department of Gastrointestinal Medical Oncology
    Division of Cancer Medicine
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Jaffer Ajani, MD, has the following relevant financial relationships:
    Consultant or advisor for: Acrotech; Amgen; Arcus; Astellas; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi; Dava; FivePrime; Geneos; Gilead; GRAIL; Innovent; Merck; More; Novartis; OncLive; Oncotherics; Serrono; Servier; Taiho; Vaccinogen; Zymeworks
    Research funding from: Astellas; Bristol Myers Squibb; Daiichi; Delta-Fly; Gilead; LaNova; Leap; Merck; Prolinx; Roche; Taiho; Turning Point; Zymeworks

  • Michelle Turner, MS, CRNP

    Thoracic Oncology Nurse Practitioner
    Manager for Solid Tumor Oncology
    John Hopkins University
    Baltimore, Maryland

    Disclosures

    Michelle Turner, MS, CRNP, has the following relevant financial relationships:
    Speaker or member of speakers bureau for: Merck

    Participation by Dr Turner does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.

Editor

  • Christin Melton, ELS

    Scientific Content Manager, Medscape, LLC 

    Disclosures

    Christin Melton, ELS, has no relevant financial relationships. 

Compliance Reviewer/Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Evolution of Checkpoint Inhibitors in Esophageal Squamous Cell Carcinoma: A Case Review

Authors: Jaffer Ajani, MD; Michelle Turner, MS, CRNPFaculty and Disclosures

CME / ABIM MOC / CE Released: 9/28/2022

Valid for credit through: 9/28/2023

processing....

Educational Impact Challenge

The goal of this activity is for learners to be better able to apply new data and expert guidance on use of checkpoint inhibitors (ICIs) in managing patients with untreated ESCC.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.